Originally published In Press as doi:10.1074/jbc.M111945200 on February 13, 2002
J. Biol. Chem., Vol. 277, Issue 17, 14793-14800, April 26, 2002
Arachidonic Acid Promotes Phosphorylation of 5-Lipoxygenase at
Ser-271 by MAPK-activated Protein Kinase 2 (MK2)*
Oliver
Werz
§¶,
Dagmar
Szellas§,
Dieter
Steinhilber§, and
Olof
Rådmark
From the
Department of Medical Biochemistry and
Biophysics, Division of Physiological Chemistry II, Karolinska
Institutet, S-171 77 Stockholm, Sweden and the § Institute
of Pharmaceutical Chemistry, University of Frankfurt,
D-60439 Frankfurt, Germany
Received for publication, December 14, 2001, and in revised form, February 6, 2002
 |
ABSTRACT |
We demonstrated previously that 5-lipoxygenase
(5-LO), a key enzyme in leukotriene biosynthesis, can be phosphorylated
by p38 MAPK-regulated MAPKAP kinases (MKs). Here we show that mutation of Ser-271 to Ala in 5-LO abolished MK2 catalyzed phosphorylation and
clearly reduced phosphorylation by kinases prepared from stimulated polymorphonuclear leukocytes and Mono Mac 6 cells. Compared with heat
shock protein 27 (Hsp-27), 5-LO was a weak substrate for MK2. However,
the addition of unsaturated fatty acids (i.e. arachidonate 1-50 µM) up-regulated phosphorylation of 5-LO, but not
of Hsp-27, by active MK2 in vitro, resulting in a similar
phosphorylation as for Hsp-27. 5-LO was phosphorylated also by other
serine/threonine kinases recognizing the motif Arg-Xaa-Xaa-Ser (protein
kinase A, Ca2+/calmodulin-dependent kinase II),
but these activities were not increased by fatty acids. HeLa cells
expressing wild type 5-LO or S271A-5-LO, showed prominent 5-LO activity
when incubated with Ca2+-ionophore plus arachidonate.
However, when stimulated with only exogenous arachidonic acid, activity
for the S271A mutant was significantly lower as compared with wild type
5-LO. It appears that phosphorylation at Ser-271 is more important for
5-LO activity induced by a stimulus that does not prominently increase
intracellular Ca2+ and that arachidonic acid stimulates
leukotriene biosynthesis also by promoting this MK2-catalyzed phosphorylation.
 |
INTRODUCTION |
5-Lipoxygenase (5-LO)1
catalyzes initial steps in formation of leukotrienes (LTs) and
lipoxins, mediators and modulators of inflammatory and allergic
reactions (1). In addition to phagocytes and B-lymphocytes, 5-LO was
recently found also in dendritic cells, implying functions for LTs also
in the adaptive part of the immune response (2, 3). Depending on the
cell type, 5-LO is present in the cytosol but also in a nuclear soluble
pool of resting cells. Upon cell stimulation, soluble 5-LO translocates
to the nuclear membrane where it colocalizes with
5-lipoxygenase-activating protein (FLAP) and cytosolic phospholipase
A2, and initializes the formation of LTs (for review
see Ref. 4). It was recently described that an N-terminal
-barrel
domain of 5-LO is important for Ca2+-stimulated membrane
association (5-7). It appears that phosphorylation is another
determinant of cellular LT biosynthesis (8, 9); cell stimulation
leading to 5-LO activity activated p38 MAPK and its downstream targets
(MAPKAP kinases (MKs)), which can phosphorylate 5-LO in
vitro, (10-13). Interestingly, the p38 MAPK inhibitor SB 203580 inhibited antigen-induced LTC4 production in sensitized mouse bone marrow-derived mast cells (14).
The mitogen-activated protein kinase (MAPK) superfamily in mammalian
cells includes p38 MAPK, which is activated when cells are exposed to
cytokines or various forms of cellular stress (for review see Ref. 14).
For PMNL and other cell types, exogenous arachidonic acid (AA) resulted
in phosphorylation and activation of p38 MAPK (15-17). In PMNL, AA
also leads to activation of another MAPK, ERK1/2 (18). Activated p38
MAPK subsequently phosphorylates and activates downstream kinases such
as MKs, as well as certain transcription factors (14). MK2
phosphorylates substrates at serine residues in the consensus motif
hyd-Xaa-Arg-Xaa-Xaa-Ser, where hyd is a bulky hydrophobic amino acid
such as Phe or Leu (19, 20). Some identified MK2 substrates are heat
shock protein 27 (Hsp-27) (21, 22), lymphocyte-specific protein (23), serum response factor, CREB (cAMP-response element-binding protein), tyrosine hydroxylase, glycogen synthases (23, 24), and vimentin (25).
We found that also 5-LO is a substrate for p38 MAPK-regulated MKs (10,
12). Here we demonstrate that Ser-271 is a phosphorylation site in 5-LO
and that unsaturated fatty acids such as AA stimulate phosphorylation
of 5-LO at Ser-271 by MK2. This phosphorylation site was more important
for 5-LO activity in transfected cells stimulated with only exogenous
AA as compared with cells stimulated with AA plus
Ca2+-ionophore.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Human transforming growth factor
was purified
from outdated platelets as described (26). 1,25-Dihydroxyvitamin
D3 was from Biomol (Plymouth Meeting, PA); RPMI 1640 from
Invitrogen; fetal calf serum, bovine insulin, protein kinase A
(PKA) catalytic subunit, human recombinant Hsp-27, arachidic acid,
linoleic acid, linolenic acid, palmitic acid, oleic acid,
Ca2+-ionophore A23187, and fMLP from Sigma; arachidonic
acid from Nu-Chek (Elysian, MN); SB203580 from Calbiochem;
[
-32P]ATP (110 TBq/mmol) from Amersham Biosciences;
HPLC solvents from Rathburn Chemicals (Walkerburn, Scotland); activated
GST-MK2 and Ca2+/calmodulin-dependent kinase
(CaMK) II from Upstate Biotechnology (Lake Placid, NY); and
oligonucleotides were from Cyber Gene (Huddinge, Sweden).
Cell Culture and Transient Transfections--
Mono Mac 6 (MM6)
cells were cultured and differentiated with transforming growth factor
and 1,25-dihydroxyvitamin D3 as described (10). Cells
were harvested by centrifugation (200 × g, 10 min at
room temperature) and washed once in phosphate-buffered saline,
pH 7.4 (PBS). Human polymorphonuclear leukocytes (PMNL) were isolated
from leukocyte concentrates obtained from healthy donors at Karolinska
Hospital. For incubations, MM6 cells and PMNL were finally resuspended
in PGC buffer (PBS with 1 mM Ca2+ and 1 mg/ml glucose).
HeLa cells were maintained in Dulbecco's modified Eagle's medium
supplemented with 10% fetal calf serum and 100 µg/ml streptomycin, 100 units/ml penicillin at 37 °C in a 5% CO2 incubator.
Plasmid DNA (pcDNA3.1-5LO, 10 µg) was transiently transfected
into HeLa and HEK-293 cells using the Ca2+-phosphate method
(27), cultured for 48 h, and assayed for 5-LO activity.
Site-directed Mutagenesis, Expression, and Purification of 5-LO
Proteins--
The codon for Ser-271 in the plasmid pT3-5LO was mutated
using the QuikChangeTM kit from Stratagene as
described (5). The mutated DNA was confirmed using the Applied
Biosystem PRISM Dye Terminator Cycle Sequencing Ready Reaction kit
(PerkinElmer Life Sciences), followed by analysis on a Applied
Biosystem PRISM 377 sequencer (carried out by KISeq, Core Facilities at
Karolinska Institutet). Escherichia coli MV1190 was
transformed with mutated and wild type (wt) DNA, and recombinant 5-LO
proteins were expressed at 27 °C and purified as described (5). The
mutated plasmid pcDNA3.1-5LO-S271A was prepared from
pcDNA3.1-5LO (28) by replacement of the EcoRV to
NotI fragment with the corresponding DNA fragment from
pT3-5LO-S271A.
In-gel Kinase Assay--
PMNL and differentiated MM6 cells
(5 × 107 and 2.5 × 107,
respectively, in 1 ml of PGC buffer) were stimulated with the indicated additives for 3 min at 37 °C. Incubations were stopped by addition of the same volume of 2× SDS-PAGE sample loading buffer (SDS-b) and
heated for 6 min at 95 °C. Total cell lysates corresponding to
0.25 × 106 MM6 cells or 0. 5 × 106
PMNL were loaded on 10% SDS-PAGE. A Mini Protean system
(Bio-Rad) was used, and the separation gels contained 0.2 mg/ml
purified recombinant human wt-5-LO or S271A-5-LO. After
electrophoresis, 5-LO phosphorylation by activated kinases was analyzed
by in-gel kinase assay as described previously (10).
Immunoprecipitation and in Vitro Kinase Assay--
For
preparation of immunoprecipitates (IPs), MM6 cell incubations were
stopped by the addition of 2 volumes of ice-cold stop buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 50 mM NaF, and 2 mM
Na3VO4) and cooled on ice. After about 2 min on ice, cells were pelleted (500 × g, 3 min, 4 °C) and
lysed by the addition of ice-cold lysis buffer (20 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 1%
Triton X-100, 0.5% Nonidet P-40, 50 mM NaF, 2 mM Na3VO4, 25 mM
-glycerophosphate, 10 mM sodium pyrophosphate, 10 mM 4-nitrophenyl phosphate, 1 mM
phenylmethylsulfonyl fluoride, 5 µM ZnCl2, 10 µg/ml leupeptin, and 60 µg/ml soybean trypsin inhibitor). During 10 min in this buffer, the suspension was vortexed repeatedly (5 s bursts)
to assure complete lysis. Supernatants were obtained by centrifugation
of the lysates (16,000 × g, 10 min, 4 °C) and kept
on ice. To immunoprecipitate MK2, supernatants corresponding to 2 × 107 MM6 cells were incubated with 5 µl of MK2-antibody
(Santa Cruz Biotechnology) for 2 h at 4 °C. The immune
complexes were precipitated (2 h at 4 °C) with 20 µl of protein
A/G Plus-agarose (Santa Cruz Biotechnology) and washed twice with lysis
buffer and twice with kinase buffer. For in vitro
phosphorylation studies, purified recombinant wt-5-LO, S271A-5-LO, and
recombinant Hsp-27 (40 pmol each) were preincubated in the absence or
presence of fatty acids in kinase buffer (25 mM HEPES, pH
7.5, 25 mM MgCl2, 25 mM
-glycerophosphate, 2 mM dithiothreitol, 0.1 mM Na3VO4) for 5 min at room
temperature. Then, kinase (MK2-IPs, MK2, CaMKII, and catalytic subunit
of PKA) was added and the reaction was started by the addition of ATP (100 µM) and [
-32P]ATP (100 µCi/ml).
The final volume was 20 µl, and incubation time was 30 min at
30 °C. The reaction was terminated by the addition of the same
volume of SDS-b and heating at 95 °C for 6 min. Samples (20 µl)
were separated by SDS-PAGE, and proteins were first visualized by
Coomassie staining to assure correct loading of protein. Phosphorylated proteins were then visualized by autoradiography and quantitated by
densitometry using a Gel Doc 1000 instrument and the Molecular Analyst
software (Bio-Rad), or alternatively they were analyzed with a
Phosphoimager (Fuji FLA-3000). Here we define 1 milliunit of
kinase activity (MK2, CaMKII, and the catalytic subunit of PKA) as
incorporation of 1 pmol of phosphate into a standard substrate peptide.
Since the standard substrates used by the suppliers are different for
the different kinases, the unit amounts are not strictly comparable.
In-gel Digestion of 5-LO and Two-dimensional Phosphopeptide
Mapping--
Purified recombinant 5-LO (3 µg or 40 pmol) was
phosphorylated in vitro by activated MK2 (10 milliunits) in
the presence of ATP (100 µM) and
[
-32P]ATP (2 µCi/ml) with or without 50 µM AA as described above. After separation of proteins by
SDS-PAGE, 5-LO was excised from the gel, and in-gel digestion of 5-LO
by trypsin was performed as described (29). The gel was extracted by
acidic, basic, and lipophilic extraction methods to recover all
peptides, and successful digestion was confirmed by MALDI analysis
(matrix-assisted laser desorption/ionization). The tryptic digests were
resuspended in glacial acetic acid and subjected to thin layer
electrophoresis and subsequent ascending chromatography as described
(30). After air drying the phosphopeptides were visualized using a
Phosphoimager Fuji FLA-3000.
Subcellular Fractionation--
Isolated human PMNL (3 × 107 in 1 ml PGC buffer) were incubated for 5 min at
37 °C with the indicated additives. Samples were chilled on ice, and
nuclear and non-nuclear fractions were obtained after cell lysis by
0.1% Nonidet P-40 as described previously (11). Aliquots of nuclear
and non-nuclear fractions were immediately mixed with the same volume
of SDS-b, heated for 6 min at 95 °C, and analyzed for 5-LO protein
by SDS-PAGE and immunoblotting.
Western Blot--
Subcellular fractions or total cell lysates
were separated by SDS-PAGE using a Mini Protean system (Bio-Rad) on a
4-15% linear gradient gel. After electroblot to nitrocellulose
membrane (Hybond C, Amersham Biosciences), blocking with 5% nonfat dry
milk in 50 mM TBS (Tris-HCl, pH 7.4, and 100 mM
NaCl), membranes were washed and then incubated with primary antibody
for overnight at 4 °C. A 5-LO column was used to produce an
affinity-purified anti-5-LO antiserum (1551, AK7). Anti-p38 MAPK
antibody was from Santa Cruz Biotechnology, and phospho-specific
antibodies recognizing p38 MAPK (Thr-180/Tyr-182) were obtained from
New England Biolabs and used as 1:2,000 dilution. Immunoreactive
proteins were visualized using alkaline phosphatase-conjugated IgGs as
described (5).
Determination of 5-Lipoxygenase Product Formation--
Cells
(5 × 106 PMNL, HeLa 2 × 106) in 1 ml of PGC buffer were stimulated by the addition of exogenous AA at the
indicated concentrations with or without ionophore. After 5 min at
37 °C, the reaction was stopped with 1 ml of methanol and 30 ml of 1 N HCl, and then 200 ng of prostaglandin B1 and
500 µl of PBS were added. 5-LO metabolites were extracted and
analyzed by HPLC as described (31). 5-LO activity is expressed as pmol
of 5-LO products per 106 cells, which includes
LTB4 and its all-trans-isomers,
5(S),12(S)-dihydroxy-6,10-trans-8,14-cis-eicosatetraenoic acid, 5-HPETE and 5-HETE.
 |
RESULTS |
Ser-271 Is Required for 5-LO Phosphorylation by Kinases from MM6
Cells and PMNL--
We showed that 5-LO is a substrate for p38
MAPK-regulated MKs in vitro, and we identified a MK2
phosphorylation motif (hyd-Xaa-Arg-Xaa-Xaa-Ser) within the primary
sequence of 5-LO with Ser-271 as the putative phosphorylation site
(10). To determine the sites of 5-LO phosphorylation by MKs, Ser-271
was mutated to alanine. Phosphorylation of wt-5-LO and S271A-5-LO was
analyzed by in-gel kinase assays using lysates from activated MM6 cells
and PMNL as sources for active kinases. Using wt-5-LO as substrate,
lysates of ionophore-stimulated MM6 cells and ionophore (or
fMLP)-stimulated PMNL contained 5-LO kinase activities migrating at
~40, 47, and 55 kDa (Fig. 1). These
bands agree which the positions of MK2 and MK3 (compare Ref. 10). With
samples from ionophore-stimulated MM6 cells, particularly the kinase
activity migrating at 47 kDa (presumably MK2) was reduced when mutated
S271A-5-LO was used as substrate. However, kinase activities at 55 and
40 kDa were still observed. When mutated S271A-5-LO was used as
substrate for kinases prepared from PMNL, activities migrating at 47 and 40 kDa were very weak, but a 55-kDa kinase activity remained, which
is best seen with the sample from cells stimulated with fMLP. It
appears that kinase activities migrating close to 40 kDa were different
in MM6 cells and PMNL. This activity from MM6 cells remained with
S271A-5-LO as substrate, but for PMNL samples (apparently two bands) it
was practically absent with S271A-5-LO as substrate. Since MK3
recognizes the same motif as MK2 (32-34), this further confirms that
the PMNL 40 kDa band is MK3. In summary, Ser-271 is important for
phosphorylation of 5-LO, but kinases recognizing other motifs were
present, particularly in extracts from stimulated MM6 cells. The MM6
cell kinase activities migrating above 57 kDa appeared also without
5-LO in the gel, which is believed to reflect autophosphorylation of
various kinases (10).

View larger version (64K):
[in this window]
[in a new window]
|
Fig. 1.
Phosphorylation of wild-type and mutated 5-LO
proteins by cellular kinases. MM6 cells (2.5 × 107) and PMNL (5 × 107) in 1 ml of PGC
buffer were stimulated with ionophore or fMLP at the indicated
concentrations for 3 min at 37 °C. Incubations were terminated by
addition of the same volume of SDS-b, vortexed, and heated at 95 °C
for 6 min. Aliquots of total cell lysates were electrophoresed on a
10% SDS-polyacrylamide gel that had been polymerized in the presence
of 0.2 mg/ml either wt- or S271A-5-LO. 5-LO phosphorylation was
analyzed by an in-gel kinase assay as described under "Experimental
Procedures." The arrows indicate kinase activities
migrating close to 55, 47, and 40 kDa.
|
|
Arachidonic Acid Enhances 5-LO Phosphorylation by MK2 in
Vitro--
To estimate the efficiency of 5-LO phosphorylation by MK2,
we compared 5-LO and Hsp-27 as substrates for MK2, by in
vitro kinase assays. Hsp-27 is phosphorylated by MK2 at three
serine residues, most efficiently on Ser-82 followed by Ser-78 and
Ser-15 (33). Purified 5-LO (40 pmol) or human Hsp-27 (40 pmol)
was incubated with the same amounts of active recombinant MK2 in
in vitro kinase assays, and phosphorylated proteins were
visualized and quantitated after SDS-PAGE. As shown in Fig.
2A, 5-LO is a rather weak
substrate for activated MK2 (10 milliunits) compared with Hsp-27.
Densitometric analysis of phosphorylated bands obtained after
audioradiography revealed that MK2 is ~20-30-fold more active toward
Hsp-27 than toward 5-LO. Similar differences in phosphorylation were
obtained when the amount of substrates or amount of MK2 was varied.
Co-incubation of 5-LO together with Hsp-27 did not reduce phosphorylation of Hsp-27, indicating that 5-LO had no inhibitory effect on kinase activity of MK2 or any phosphatase activity (data not
shown).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 2.
Arachidonate stimulates 5-LO phosphorylation
by MK2 at Ser-271. Phosphorylation of 5-LO proteins and Hsp-27 by
MK2 was determined by in vitro kinase assays as described
under "Experimental Procedures." The same amounts (40 pmol) of 5-LO
proteins and Hsp-27 was incubated with 10 milliunits of active MK2 and
the indicated amounts of AA. After incubation at 30 °C for 30 min,
the samples were heated and aliquots were subjected to SDS-PAGE.
Phosphorylated proteins were visualized by autoradiography and
quantitated by densitometry. A, comparison of
phosphorylation of 5-LO and Hsp-27. The relative phosphorylation of the
proteins (shown under the lanes) was calculated as the ratio
of the radioactivity intensities of phosphorylated Hsp-27 and
phosphorylated 5-LO. Results are representative of three separate
experiments. B, effects of increasing amounts of AA on MK2
activity toward 5-LO and Hsp-27. The relative phosphorylation of 5-LO
and Hsp-27, respectively, was calculated as the ratio of the
radioactivity intensities within each series. Results are
representative of three separate experiments. C,
phosphorylation of wt- and S271A-5-LO proteins by MK2 and effects of
AA. D, two-dimensional tryptic phosphopeptide maps of 5-LO,
phosphorylated in the absence (w/o, left panel)
or presence of AA (right panel). 5-LO (40 pmol) was
incubated with 10 milliunits of active MK2 with or without 50 µM AA for 30 min at 30 °C, and proteins were separated
by SDS-PAGE. After in-gel digestion of 5-LO by trypsin, the
phosphopeptides were separated in two dimensions on thin layer
chromatography plates as described under "Experimental Procedures."
The arrows indicate the major phosphopeptide.
|
|
AA dose-dependently enhanced 5-LO
phosphorylation by MK2, about 3-fold at 1 µM AA and up to
about 30-fold at 50 µM AA as shown in Fig. 2B
(left panel). Thus, in the presence of AA, MK2 efficiently phosphorylates 5-LO, comparable with Hsp-27. Ca2+ (0.01-1
mM) and phosphatidylcholine (20 µg/ml), as well as
cellular soluble or particulate fractions (which can increase catalytic activity of 5-LO in vitro) gave no such up-regulation but
rather reduced MK2 activity toward 5-LO in the absence or presence of AA (data not shown). In contrast to 5-LO, no increase in
phosphorylation of Hsp-27 was obtained after adding AA to the reaction
mixture (Fig. 2B, right panel). Higher amounts of
MK2 augmented Hsp-27 phosphorylation dose-dependently,
indicating that substrate supply was not a limiting factor.
This effect of AA could be related to phosphorylation of other sites in
5-LO, in addition to Ser-271. Therefore, we investigated whether AA
induced phosphorylation of the S271A mutant by MK2. The same amounts of
wt- and S271A-5-LO proteins were used in in vitro kinase
assays with active MK2 as kinase (Fig. 2C, upper panel). Prior to drying and exposure of the gels, Coomassie
staining was performed to ensure correct loading of 5-LO proteins
(lower panel). As shown in Fig. 2C, S271A-5-LO
was not a substrate for MK2 in vitro neither in the absence
or presence of AA.
Enhanced 5-LO phosphorylation in the presence of AA might be due to
phosphate incorporation at additional sites of 5-LO by MK2, which
require initial phosphorylation at Ser-271. Therefore, two-dimensional
phosphopeptide analyses of 5-LO incubated with MK2 in the presence or
absence of AA (50 µM) were performed. As seen in Fig.
2D, only one major phosphopeptide was detectable in both
samples. For the sample derived from 5-LO that was phosphorylated in
the presence of 50 µM AA, the signal of this
phosphopeptide was much more intense as compared with the control.
Thus, AA apparently increases 5-LO phosphorylation at one major site
(Ser-271) but does not lead to phosphorylation at additional sites. The
faint spots on the left of the plates (seen for both samples) might result from incomplete trypsin digestion.
Unsaturated but Not Saturated Fatty Acids Stimulate Phosphorylation
of 5-LO--
We also determined the capability of other long chain
fatty acids to stimulate phosphorylation of 5-LO by MK2. The results in
Fig. 3 illustrate that oleic acid
(C18:1) was effective. Compared with AA, the concentration of
oleic acid required for the same effect appeared to be slightly lower.
Similar dose-dependent up-regulation of 5-LO
phosphorylation by MK2 was observed with linoleic acid (C18:2) and
linolenic acid (C18:3) at 10-50 µM (data not shown). In contrast, arachidic acid (C20:0) (the saturated derivative of
AA) or palmitic acid (C16:0) up to 50 µM caused only
marginal enhancement of 5-LO phosphorylation (Fig. 3). Also oxygenated metabolites of polyunsaturated fatty acids (13-HPODE, 5-HPETE, LTB4) gave only slight (about 2-4-fold) increase in 5-LO
phosphorylation (not shown). No enhancement of phosphorylation was
obtained with esterified fatty acids (oleyl-acetyl-glycerol, mixed
phosphatidylcholines; data not shown). These findings indicate that
efficient phosphorylation of 5-LO by MK2 in vitro requires
the presence of free unsaturated fatty acids.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 3.
Only unsaturated fatty acids stimulate 5-LO
phosphorylation by MK2. The effects of fatty acids on 5-LO
phosphorylation were determined by in vitro kinase assays as
described under "Experimental Procedures." 5-LO (40 pmol) was
incubated with 10 milliunits of MK2 in the absence or presence of the
indicated fatty acids at 10, 25, or 50 µM. Proteins were
separated by SDS-PAGE, and phosphorylated 5-LO was visualized and
quantitated by Phosphoimager. The relative phosphorylation of the
samples was calculated by the ratio of the radioactivity intensities,
and the control without fatty acid was set as 1. Results are
representative of three separate experiments.
|
|
Arachidonic Acid Specifically Stimulates 5-LO Phosphorylation by
MK2 but Not by CaMKII or PKA--
The MK2 phosphorylation motif,
hyd-Xaa-Arg-Xaa-Xaa-Ser, is also recognized by other basic amino
acid-directed Ser/Thr kinases (for example PKC, PKA, and CaMK II and
IV). Thus, we tested whether kinases other than MKs could phosphorylate
5-LO in in vitro kinase assays (Fig.
4). The catalytic subunit of PKA as well
as CaMKII phosphorylated 5-LO in a dose-dependent manner.
Interestingly, PKA and CaMKII also phosphorylated Hsp-27 (not shown).
The amounts of kinases used are given in units as provided by the
suppliers. Please note that the unit definitions for these kinases are
based on different synthetic substrates and may not be directly
comparable. As found for MK2, PKA was unable to phosphorylate
S271A-5-LO, indicating that PKA also acts on the Ser-271 residue (not
shown). As demonstrated in Fig. 5, the
presence of AA (or oleic acid, not shown) during the kinase reaction
did not enhance the phosphorylation rates of CaMKII and PKA toward
5-LO. In contrast, fatty acids rather inhibited the kinase activity of
CaMKII toward 5-LO as well as its autophosphorylation (Fig. 5) as
observed by other investigators (35).

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 4.
5-LO is phosphorylated by CaMKII and
PKA. 5-LO phosphorylation was determined by in vitro
kinase assay as described under "Experimental Procedures" except
that 1 mM CaCl2 and 50 µg/ml calmodulin were
added to incubations with CaMKII. In all incubations 40 pmol of 5-LO
was used. One milliunit of each kinase (MK2, CaMKII, and the catalytic
subunit of PKA) incorporates 1 pmol of phosphate into a standard
substrate peptide. Since the standard substrates are different for the
different kinases, the unit amounts are not strictly comparable.
Proteins were separated by SDS-PAGE, and phosphorylated 5-LO was
visualized by Phosphoimager. Results are representative of three
separate experiments.
|
|

View larger version (44K):
[in this window]
[in a new window]
|
Fig. 5.
Arachidonic acid stimulates 5-LO
phosphorylation by MK2 but not by CaMKII and PKA. Effects of AA on
phosphorylation of 5-LO by different kinases was determined by in
vitro kinase assays as described under "Experimental
Procedures" except that 1 mM CaCl2 and 50 µg/ml calmodulin were added to incubations with CaMKII. 40 pmol of 5-LO and 10 milliunits of MK2, CaMKII, and the catalytic
subunit of PKA were used. For unit definitions, see the legend for Fig.
4. Proteins were separated by SDS-PAGE, and phosphorylated 5-LO was
visualized by autoradiography. Results are representative of three
separate experiments.
|
|
Effect of Phosphorylation on Ca2+-stimulated 5-LO
Catalytic Activity in Vitro--
To determine the effects of 5-LO
phosphorylation by MK2, PKA, and CaMKII on the activity of the enzyme,
purified recombinant 5-LO (0.2 µg) was preincubated with 10 milliunits of kinase in kinase buffer with 100 µM ATP (20 µl final volume). After 30 or 60 min at 30 °C, 5-LO (0.1 µg in
10 µl) was added to a 5-LO activity assay substrate mix (990 µl,
containing Ca2+, phosphatidylcholine, ATP, 13-HPODE,
and AA) to start the 5-LO reaction (compare Ref. 5). After 10 min the
incubation was terminated, and 5-HPETE plus 5-HETE formation was
determined by HPLC. In another set of incubations, kinases were added
simultaneously (no preincubation) with the substrate mix. There was no
appreciable effect on 5-LO activity, and at most about a 1.2-fold
up-regulation was observed. Also, the activity of purified mutated
S271A-5-LO protein in in vitro assay was comparable with the
activity of wt-5-LO.
Arachidonic Acid Activates p38 MAPK-regulated 5-LO Kinases in
Leukocytes--
It was shown previously that p38 MAPK is activated by
AA in a cell type-specific manner, for example in PMNL, HL60, and HeLa cells but not in a T cell line (Jurkat) (15). To determine the activation of p38 MAPK and 5-LO kinases by AA in MM6 cells and PMNL,
cells were stimulated with increasing concentrations of AA for 3 min
and lysed by the addition of SDS-b, and total cell lysates were
prepared. Activation of p38 MAPK-regulated 5-LO kinases was analyzed by
in-gel kinase assays using 5-LO as substrate. As shown in Fig.
6A, AA (10-100
µM) led to activation of 5-LO kinases in MM6 cells,
particularly at 47 kDa (presumably MK2), which is similar to the
positive control (cells stimulated with ionophore) and to results with
ionophore-stimulated MM6 cells in Fig. 1. In other experiments,
activation of the 47-kDa kinase in MM6 cells was apparent already at 3 µM AA (not shown). Activation of MK2 in MM6 cells was
determined also after immunoprecipitation of the kinase and subsequent
in vitro kinase assay using 5-LO as substrate. 5-LO kinase
activity was increased in MK2-IPs from cells stimulated with AA in a
dose-response fashion (see Fig. 6B). At the highest
concentration of AA (100 µM) 5-LO kinase activity was
almost as high as that obtained with MK2-IPs from cells stimulated with
5 µM ionophore A23187. Activation of p38 MAPK was
determined by Western blotting using an antibody that detects only the
dually phosphorylated (activated) form of the kinase. Stimulation of MM6 cells with AA led to activation of p38 MAPK (Fig. 6C),
which seemed to correlate with the activation of 5-LO kinases (compare Fig. 6, panels A and B). Similarly, 5-LO kinase
activity was obtained in AA-stimulated PMNL when cell lysates
were analyzed by in-gel kinase assay (Fig. 6D). In contrast
to cells stimulated with ionophore, lysates of AA-challenged PMNL gave
only weak bands for the 40-kDa kinase (presumably MK3).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 6.
Stimulation of p38 MAPK and p38
MAPK-regulated 5-LO kinases by AA. A, MM6 cells
(2.5 × 106) in 100 µl of PGC buffer were stimulated
with ionophore or AA at the indicated concentrations for 3 min at
37 °C. Incubations were terminated by addition of the same volume of
SDS-b, vortexed, and heated at 95 °C for 6 min. Aliquots (0.25 × 106) of total MM6 cell lysates were electrophoresed on a
10% SDS-polyacrylamide gel that had been polymerized in the presence
of 0.2 mg/ml 5-LO. 5-LO phosphorylation was analyzed by in-gel kinase
assay as described under "Experimental Procedures." Results are
representative of two separate experiments. The arrows
indicate kinase activities migrating close to 47 and 40 kDa.
B, MM6 cells (1 × 107 in 1 ml of PGC
buffer) were incubated for 3 min at 37 °C as indicated, and MK2 was
immunoprecipitated as described under "Experimental Procedures."
MK2-IPs were incubated with purified recombinant 5-LO in the presence
of 50 µM AA, ATP (100 µM), and
[ -32P]ATP (2 µCi/ml). The final volume was 20 µl,
and incubation time was 30 min at 30 °C. Proteins were separated by
SDS-PAGE, and phosphorylated proteins were analyzed with a Fuji
FLA-3000 Phosphoimager. C, MM6 cells (2.5 × 106) in 100 µl of PGC buffer were stimulated with AA at
the indicated concentrations for 3 min at 37 °C. Incubations were
terminated by addition of the same volume of SDS-b, vortexed, and
heated at 95 °C for 6 min. Aliquots (0.25 × 106)
of total MM6 cell lysates were electrophoresed, and immunoblotting was
performed using a specific antibody that detects the dually
phosphorylated form of p38 MAPK (upper panel). Equal sample
loading was demonstrated with anti-p38 MAPK antibodies (lower
panel). D, PMNL (5 × 106) in 100 µl
of PGC buffer were stimulated with ionophore or AA at the indicated
concentrations for 3 min at 37 °C. Incubations were terminated by
addition of the same volume of SDS-b, vortexed, and heated at 95 °C
for 6 min. Aliquots (0.5 × 106) of total PMNL cell
lysates were electrophoresed on a 10% SDS-polyacrylamide gel that had
been polymerized in the presence of 0.2 mg/ml 5-LO. 5-LO
phosphorylation was analyzed by in-gel kinase assay. The
arrows indicate kinase activities migrating close to 47 and
40 kDa.
|
|
AA Stimulates 5-LO Activity and Translocation to the Nucleus in
PMNL--
In a recent report it was shown that exogenous AA induced
5-LO enzyme activity and translocation to the nucleus in
adenosine-depleted PMNL (36), and we have confirmed that AA also
contributes to nuclear translocation of 5-LO in MM6 cells (11). Here we
found that stimulation of PMNL with AA (5-50 µM)
resulted in a modest but dose-dependent 5-LO activation
(Fig. 7A). For comparison, in
different experiments the 5-LO activity induced by 40 µM
AA was 10-20% of the activity obtained after stimulation with
ionophore only (2.5 µM) without the addition of exogenous
AA (data not shown). Already in resting cells, a small amount of 5-LO
was associated with the nucleus, but a high concentration of AA was
required (50 µM) for a clearly increased translocation of
5-LO to nuclear structures, comparable with that obtained with
ionophore (Fig. 7B). Thus, we could confirm that exogenous
AA leads to 5-LO translocation in PMNL, but stimulation of activity was
seen at lower concentrations of AA than were needed to induce
translocation. We performed these experiments in the absence of
adenosine deaminase, which possibly explains the high concentration of
AA required to induce translocation of 5-LO to the nucleus (50 µM as compared with 3 µM in Ref. 36).

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 7.
Effects of arachidonic acid on 5-LO product
formation and 5-LO distribution in PMNL. A, for
determination of 5-LO product formation in intact cells, human PMNL
(7.5 × 106 in 1 ml of PGC buffer) were stimulated
with the indicated concentrations of AA for 5 min at 37 °C. 5-LO
product formation was determined by HPLC as described under
"Experimental Procedures." Results are given as mean ± S.E., n = 3. B, for determination of 5-LO
distribution, PMNL (3 × 107 in 1 ml of PGC buffer)
were stimulated with the indicated additives for 5 min at 37 °C.
Cell fractionation and immunoblotting was performed as described under
"Experimental Procedures." Pairwise samples (non-nuclear
and nuclear) correspond to the identical cell numbers.
Similar results were obtained in two additional independent
experiments.
|
|
Role of Ser-271 for 5-LO Product Formation in Transformed
Cells--
HeLa cells were transiently transformed with plasmids
encoding wt-5-LO or S271A-5-LO. The expression levels of wt-5-LO and S271A-5-LO were similar, as determined by Western blot
(inset in Fig. 8). Transformed
cells were stimulated with ionophore plus exogenous AA or only with
exogenous AA, and 5-LO products were determined by HPLC. As shown in
Fig. 8, HeLa cells expressing wild type or mutated 5-LO, stimulated
with both ionophore (10 µM) and AA (0-80
µM), gave similar prominent product formations. However,
when transformed cells were stimulated with AA only (10-80 µM), 5-LO activity for the S271A mutant was significantly
lower as compared with wt-5-LO. Particularly at 10 µM AA,
5-LO activities were strikingly different. 5-LO activity for the S271A
mutant was 15 ± 2 pmol/106 cells compared with
155 ± 70 pmol/106 cells for the wt-5-LO. At 40-60
µM AA, for S271A-5-LO activities after incubation with AA
were 24-30% of activities after incubation with AA plus ionophore;
the corresponding numbers for wild-type 5-LO were 54-63%. Similar
results were obtained also after transfections of HEK-293 cells. This
indicates that phosphorylation at Ser-271 is more important for
activation of 5-LO in cells stimulated only with AA as compared with
cells receiving both ionophore and AA.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 8.
5-LO product formation in HeLa cells
transformed with wt-5-LO and S271A-5-LO. HeLa cells were
transiently transformed with plasmids pcDNA3.1-5LO or
pcDNA3.1-5LO-S271A (10 µg). Cells (2 × 106)
were resuspended in 1 ml of PGC buffer and stimulated with the
indicated concentrations of AA in the absence of or together with 10 µM ionophore for 10 min at 37 °C. 5-LO product
formation was determined by HPLC. Results are given as mean ± S.E., n = 4. For one set of HeLa samples (total cell
lysates corresponding to 0.1 × 106 cells) the
expression of 5-LO proteins was analyzed by Western blot
(inset).
|
|
 |
DISCUSSION |
In a previous paper (10) we reported that MKs prepared from
stimulated leukocytes could phosphorylate 5-LO in vitro,
which could be one factor determining cellular 5-LO activity. Here we show that Ser-271 is a phosphorylation site in 5-LO. Thus, mutation of
Ser-271 to Ala resulted in a protein that was no longer a substrate for
active recombinant MK2 in vitro. Also, when S271A-5-LO was used as substrate in in-gel kinase assays, phosphorylation by kinases
prepared from PMNL (probably MK2 and MK3) was severely hampered.
Phosphorylation by kinases prepared from MM6 cells was also reduced
(particularly the 47-kDa band containing MK2), but other kinase
activities remained, indicating that MM6 cell kinases may recognize
also other phosphorylation sites in 5-LO.
In comparison with Hsp-27, 5-LO was a rather poor substrate for MK2
in vitro. However, the addition of AA or other unsaturated fatty acids (oleic acid, linoleic acid, linolenic acid) to the reaction
mixture strongly stimulated phosphorylation of 5-LO by MK2. In the
presence of 50 µM AA, phosphorylation of 5-LO and Hsp-27
were about equal. It was required that the fatty acid be non-esterified; oxygenated fatty acids (e.g. 13-HpODE,
5-HPETE, LTB4) were less effective, and saturated fatty
acids (arachidic acid and palmitic acid) had no effect. The motif
hyd-Xaa-Arg-Xaa-Xaa-Ser (where hyd is a bulky hydrophobic residue) is
recognized by MK2/3 and also by other kinases. Indeed, the catalytic
subunits of PKA and CaMKII were also found to phosphorylate 5-LO
in vitro. However, neither MK2-mediated phosphorylation of
Hsp-27 nor 5-LO phosphorylation by other 5-LO kinases (PKA or CaMKII)
were increased by AA. Rather, the activity of CaMKII was reduced, and
it was shown previously that fatty acids inhibit the activity of CaMKII
(35) as well as of PKA type II holoenzyme but not of the catalytic
subunit of PKA (37). The nature of the specific AA effect is unknown. Binding of AA may lead to a conformation change of 5-LO that favors the
accession of Ser-271 by MK2. In this context, it is of interest that
5-LO (and other lipoxygenases) may have two fatty acid binding sites,
one catalytic and one regulatory (38-40). Another possibility was that
binding of AA to 5-LO could lead to exposure of another MK2
phosphorylation site in 5-LO. However, also in the presence of AA,
there was no phosphorylation of S271A-5-LO by MK2 in vitro, and two-dimensional phosphopeptide mapping of trypsinized 5-LO revealed
one major phosphopeptide after in vitro phosphorylation in
the absence as well as presence of AA (Fig. 2D). Because
phosphate incorporation into this peptide was much higher for the
sample derived from 5-LO that was phosphorylated in the presence of AA, it seems that AA promotes 5-LO phosphorylation at Ser-271.
AA is released from phospholipids in many cell types (41), and it is
well established that transcellular mechanisms for the release and
uptake of free AA between cells occur (42, 43). In addition to its
function as substrate for eicosanoid biosynthesis, AA modulates several
signaling pathways at multiple levels. Free AA can modify the activity
of phospholipases, protein kinases, G-proteins, adenylate, and
guanylate cyclases, as well as ion channels (for review see Ref. 44).
PKC is directly activated by cis-unsaturated fatty acids such as AA or
oleate in vitro, and attention has been directed to the role
of AA in activating PKC under physiological conditions (44, 45). AA can
also lead to activation of p38 MAPK pathways in PMNL (15, 17) and in mammary carcinoma cells, where the activation of MK2 also was determined (16). The activation of p38 MAPK in human and rat PMNL seems
to be independent of conversion to eicosanoids, but apparently it is
partially PKC-mediated (15, 17). Also an involvement of Rac1 has been
described in AA-induced p38 MAPK activation (46, 47); and quite
recently it was presented that in Rat2-RacN17 cells (expressing a
dominant negative Rac1 mutant), ionomycin-induced translocation of a
GFP-5-LO fusion protein construct was impaired (48). We confirmed the
activation of p38 MAPK and MK2 by AA for MM6 cells and PMNL (Fig. 6).
AA is the most abundant free fatty acid in intact cells, and it has
biological activity at concentrations that can exist in stimulated
cells (1-20 µM) (15). In isolated islets of Langerhans,
glucose was found to increase cell-associated free AA up to 75 µM (49). In our study, 1-50 µM AA led to
an up to 29-fold increase of 5-LO phosphorylation by MK2 in
vitro. Similar promotion of 5-LO phosphorylation by MK2 was
observed with oleate, which was somewhat more effective than AA. Oleate
is the most abundant (100-150 µM) extracellular free
fatty acid in plasma (50), and it was demonstrated that oleate is
released during stimulation of macrophages by lipopolysaccharide (51).
It is intriguing that AA leads to activation of p38 MAPK in
neutrophils, which in turn phosphorylates and activates MK2/3, and that
AA also specifically stimulates the phosphorylation of 5-LO by MK2.
Furthermore, AA is the most common 5-LO substrate, being converted to
LTA4; AA has been implicated in a novel pathway for
noncapacitative Ca2+ entry (52). Thus, it appears that AA
dose-dependent stimulation of LT biosynthesis (Fig.
6A) involves several mechanisms.
In optimized enzyme assays providing cofactors required for full
activity of 5-LO in vitro, phosphorylation of 5-LO by MK2 (or PKA or CaMKII) caused no change in the (prominent) catalytic activity of the isolated enzyme. Also, in this assay mutated S271A-5-LO protein had approximately the same activity as 5-LO. These results indicate that phosphorylation may not directly affect catalysis of 5-LO
in vitro. However, phosphorylation of 5-LO apparently alters
product formation in intact cells. Thus, when eukaryotic cell lines
lacking expression of endogenous 5-LO (HeLa, HEK-293) were transiently
transfected with wt-5-LO and with the mutant S271A-5-LO, formation of
5-LO products was significantly lower for the mutant (than for wt-5-LO)
when the cells were stimulated with AA only as compared with cells
stimulated with AA and ionophore (Fig. 8). In PMNL stimulated with AA,
the intracellular Ca2+ concentration increases but not to
the same extent as caused by Ca2+ ionophores (13, 53, 54).
In analogy with cytosolic phospholipase A2 (55, 56), it
seems possible that phosphorylation of 5-LO at Ser-271 is more
important for 5-LO activity when cells are subjected to a stimulus that
does not lead to a profound increase in intracellular Ca2+.
This is in accordance with our previous observation that sodium arsenite (which stimulates p38 MAPK, which in turn activates MK2) led
to 4-fold increase in 5-LO activity in PMNL also receiving exogenous AA
and platelet-activating factor, whereas sodium arsenite had no effect
on cells also receiving ionophore (10). We also found that different
forms of cell stress together with exogenous AA (no ionophore) was
sufficient to stimulate 5-LO activity in BL41-E95-A lymphocytes and in
PMNL even after chelation of Ca2+ (12, 13).
In a recent study utilizing adenosine-depleted PMNL, it was shown that
AA-induced Ca2+ mobilization depends on conversion to
LTB4, and a model for AA-induced LT biosynthesis by
autocrine stimulation was presented (36). This model implied that
already membrane-bound 5-LO catalyzed an initial burst of
LTB4 biosynthesis in the absence of measurable Ca2+ mobilization. One could visualize that AA-induced
phosphorylation of 5-LO as described in this study could contribute to
such activation of 5-LO. An N-terminal C2-like
-barrel domain in
5-LO binds Ca2+ and mediates association of 5-LO with
phospholipids (5-7). A comparison with other enzymes containing
Ca2+ binding C2 domains suggests how phosphorylation could
increase activity of 5-LO. For protein kinase C
II, it was proposed
that phosphorylation at Ser-660 (outside of the C2 domains) stimulated activity by increasing the Ca2+ affinity and thus the
affinity for phosphatidyl serine (57). For cytosolic phospholipase
A2, it was concluded that the C2 domain together with
another region of the protein (subject to phosphorylation) both
contributed to membrane binding and thus activity (55, 56). It appears
possible that phosphorylation of 5-LO at Ser-271 could stimulate 5-LO
activity by similar mechanisms.
 |
ACKNOWLEDGEMENTS |
We thank Agneta Nordberg and Astrid Neu
for expert technical assistance, Carina Palmberg for MALDI analysis,
and Dr. Patrick Provost for kindly providing the plasmid
pcDNA3.1-5LO.
 |
FOOTNOTES |
*
This study was supported by grants from the Swedish Medical
Research Council (03X-217), the European Union (QLG1-CT-2001-01521), and the Verum Foundation.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Recipient of a Karolinska Institute Guest Scientist fellowship.
To whom correspondence should be addressed. Tel.:
46-8-728-7624; Fax: 46-8-736-0439; E-mail:
olof.radmark@mbb.ki.se.
Published, JBC Papers in Press, February 13, 2002, DOI 10.1074/jbc.M111945200
 |
ABBREVIATIONS |
The abbreviations used are:
5-LO, 5-lipoxygenase;
AA, arachidonic acid;
CaMKII, Ca2+/calmodulin-dependent kinase II;
ERK, extracellular signal-regulated kinase;
fMLP, formyl-methionyl-leucyl-phenylalanine;
HEK-293 cells, human embryonic
kidney 293 cells;
Hsp-27, heat shock protein 27;
IP, immunoprecipitate;
LT, leukotriene;
MAPK, mitogen-activated protein kinase;
MAPKAP, mitogen-activated protein kinase-activated protein;
MK, MAPKAP kinase;
MM6 cells, Mono Mac 6 cells;
PBS, phosphate-buffered saline, pH 7.4;
PKA and PKC, protein kinase A and C, respectively;
PMNL, polymorphonuclear leukocytes;
SDS-b, 2× SDS-PAGE sample loading
buffer;
wt, wild type;
5-HETE, 5(S)-hydroxy-6-trans-8,11,14-cis-eicosatetraenoic
acid;
5-HPETE, 5(S)-hydroperoxy-6-trans-8,11,14-cis-eicosatetraenoic
acid;
13-HPODE, 13(S)-hydroperoxy-9-cis-11-trans-octadecadienoic
acid.
 |
REFERENCES |
| 1.
|
Samuelsson, B.,
Dahlén, S.-E.,
Lindgren, J.-Å.,
Rouzer, C. A.,
and Serhan, C. N.
(1987)
Science
237,
1171-1176[Abstract/Free Full Text]
|
| 2.
|
Spanbroek, R.,
Hildner, M.,
Steinhilber, D.,
Fusenig, N.,
Yoneda, K.,
Rådmark, O.,
Samuelsson, B.,
and Habenicht, A. J. R.
(2000)
Blood
96,
3857-3865[Abstract/Free Full Text]
|
| 3.
|
Robbiani, D. F.,
Finch, R. A.,
Jäger, D.,
Muller, W. A.,
Sartorelli, A. C.,
and Randolph, G. J.
(2000)
Cell
103,
757-768[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Peters-Golden, M.,
and Brock, T. G.
(2001)
FEBS Letters
487,
323-326[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Hammarberg, T.,
Provost, P.,
Persson, B.,
and Radmark, O.
(2000)
J. Biol. Chem.
275,
38787-38793[Abstract/Free Full Text]
|
| 6.
|
Chen, X. S.,
and Funk, C. D.
(2001)
J. Biol. Chem.
276,
811-818[Abstract/Free Full Text]
|
| 7.
|
Kulkarni, S.,
Das, S.,
Funk, C. D.,
Murray, D.,
and Cho, W.
(2002)
J. Biol. Chem.
277,
13167-13174[Abstract/Free Full Text]
|
| 8.
|
Peters-Golden, M.,
McNish, R. W.,
Sporn, P. H.,
and Balazovich, K.
(1991)
Am. J. Physiol.
261,
L462-L471[Medline]
[Order article via Infotrieve]
|
| 9.
|
Lepley, R. A.,
Muskardin, D. T.,
and Fitzpatrick, F. A.
(1996)
J. Biol. Chem.
271,
6179-6184[Abstract/Free Full Text]
|
| 10.
|
Werz, O.,
Klemm, J.,
Samuelsson, B.,
and Radmark, O.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
5261-5266[Abstract/Free Full Text]
|
| 11.
|
Werz, O.,
Klemm, J.,
Samuelsson, B.,
and Radmark, O.
(2001)
Blood
97,
2487-2495[Abstract/Free Full Text]
|
| 12.
|
Werz, O.,
Klemm, J.,
Radmark, O.,
and Samuelsson, B.
(2001)
J. Leukocyte Biol.
70,
830-838[Abstract/Free Full Text]
|
| 13.
|
Werz, O.,
Bürkert, E.,
Samuelsson, B.,
Radmark, O.,
and Steinhilber, D.
(2002)
Blood
99,
1044-1052[Abstract/Free Full Text]
|
| 14.
|
Lee, J. C.,
Kumar, S.,
Griswold, D. E.,
Underwood, D. C.,
Votta, B. J.,
and Adams, J. L.
(2000)
Immunopharmacology
47,
185-201[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Hii, C. S.,
Huang, Z. H.,
Bilney, A.,
Costabile, M.,
Murray, A. W.,
Rathjen, D. A.,
Der, C. J.,
and Ferrante, A.
(1998)
J. Biol. Chem.
273,
19277-19282[Abstract/Free Full Text]
|
| 16.
|
Paine, E.,
Palmantier, R.,
Akiyama, S. K.,
Olden, K.,
and Roberts, J. D.
(2000)
J. Biol. Chem.
275,
11284-11290[Abstract/Free Full Text]
|
| 17.
|
Chang, L. C.,
and Wang, J. P.
(2000)
J. Pharm. Pharmacol.
52,
539-546[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Capodici, C.,
Pillinger, M. H.,
Han, G.,
Philips, M. R.,
and Weissmann, G.
(1998)
J. Clin. Invest.
102,
165-175[Medline]
[Order article via Infotrieve]
|
| 19.
|
Stokoe, D.,
Campbell, D. G.,
Nakielny, S.,
Hidaka, H.,
Leevers, S. J.,
Marshall, C.,
and Cohen, P.
(1992)
EMBO J.
11,
3985-3994[Medline]
[Order article via Infotrieve]
|
| 20.
|
Stokoe, D.,
Caudwell, B.,
Cohen, P. T.,
and Cohen, P.
(1993)
Biochem. J.
296,
843-849[Medline]
[Order article via Infotrieve]
|
| 21.
|
Landry, J.,
Lambert, H.,
Zhou, M.,
Lavoie, J. N.,
Hickey, E.,
Weber, L. A.,
and Anderson, C. W.
(1992)
J. Biol. Chem.
267,
794-803[Abstract/Free Full Text]
|
| 22.
|
Rouse, J.,
Cohen, P.,
Trigon, S.,
Morange, M.,
Alonso-Llamazares, A.,
Zamanillo, D.,
Hunt, T.,
and Nebreda, A. R.
(1994)
Cell
78,
1027-1037[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Huang, C. K.,
Zhan, L., Ai, Y.,
and Jongstra, J.
(1997)
J. Biol. Chem.
272,
17-19[Abstract/Free Full Text]
|
| 24.
|
Heidenreich, O.,
Neininger, A.,
Schratt, G.,
Zinck, R.,
Cahill, M. A.,
Engel, K.,
Kotlyarov, A.,
Kraft, R.,
Kostka, S.,
Gaestel, M.,
and Nordheim, A.
(1999)
J. Biol. Chem.
274,
14434-14443[Abstract/Free Full Text]
|
| 25.
|
Cheng, T. J.,
and Lai, Y. K.
(1998)
J. Cell. Biochem.
71,
169-181[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Werz, O.,
Brungs, M.,
and Steinhilber, D.
(1996)
Pharmazie
51,
893-896[Medline]
[Order article via Infotrieve]
|
| 27.
|
Chen, C. A.,
and Okayama, H.
(1988)
BioTechniques
6,
632-638[Medline]
[Order article via Infotrieve]
|
| 28.
|
Provost, P.,
Doucet, J.,
Hammarberg, T.,
Gerisch, G.,
Samuelsson, B.,
and Rådmark, O.
(2001)
J. Biol. Chem.
276,
16520-16527[Abstract/Free Full Text]
|
| 29.
|
Shevchenko, A.,
Wilm, M.,
Vorm, O.,
and Mann, M.
(1996)
Anal. Chem.
68,
850-858[Medline]
[Order article via Infotrieve]
|
| 30.
|
de Carvalho, M. G. S.,
McCormack, A. L.,
Olson, E.,
Ghomashchi, F.,
Gelb, M. H.,
Yates, J. R., III,
and Leslie, C. C.
(1996)
J. Biol. Chem.
271,
6987-6997[Abstract/Free Full Text]
|
| 31.
|
Werz, O.,
and Steinhilber, D.
(1996)
Eur. J. Biochem.
242,
90-97[Medline]
[Order article via Infotrieve]
|
| 32.
|
Sithanandam, G.,
Latif, F.,
Duh, F. M.,
Bernal, R.,
Smola, U., Li, H.,
Kuzmin, I.,
Wixler, V.,
Geil, L.,
and Shrestha, S.
(1996)
Mol. Cell. Biol.
16,
868-876[Abstract]
|
| 33.
|
Clifton, A. D.,
Young, P. R.,
and Cohen, P.
(1996)
FEBS Lett.
392,
209-214[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
New, L.,
Jiang, Y.,
Zhao, M.,
Liu, K.,
Zhu, W.,
Flood, L. J.,
Kato, Y.,
Parry, G. C.,
and Han, J.
(1998)
EMBO J.
17,
3372-3384[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Piomelli, D.,
Wang, J. K.,
Sihra, T. S.,
Nairn, A. C.,
Czernik, A. J.,
and Greengard, P.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
8550-8554[Abstract/Free Full Text]
|
| 36.
|
Surette, M. E.,
Krump, E.,
Picard, S.,
and Borgeat, P.
(1999)
Mol. Pharmacol.
56,
1055-1062[Abstract/Free Full Text]
|
| 37.
|
Doolan, C. M.,
and Keenan, A. K.
(1994)
Br. J. Pharmacol.
111,
509-514[Medline]
[Order article via Infotrieve]
|
| 38.
|
Aharony, D.,
and Stein, R. L.
(1986)
J. Biol. Chem.
261,
11512-11519[Abstract/Free Full Text]
|
| 39.
|
Sailer, E. R.,
Schweizer, S.,
Boden, S. E.,
Ammon, H. P. T.,
and Safayhi, H.
(1998)
Eur. J. Biochem.
256,
364-368[Medline]
[Order article via Infotrieve]
|
| 40.
|
Mogul, R.,
Johansen, E.,
and Holman, T. R.
(2000)
Biochemistry
39,
4801-4807[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Dennis, E. A.
(1997)
Trends Biochem. Sci.
22,
1-2[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Antoine, C.,
Murphy, R. C.,
Henson, P. M.,
and Maclouf, J.
(1992)
Biochim. Biophys. Acta
1128,
139-146[Medline]
[Order article via Infotrieve]
|
| 43.
|
Sala, A.,
Zarini, S.,
Folco, G.,
Murphy, R. C.,
and Henson, P. M.
(1999)
J. Biol. Chem.
274,
28264-28269[Abstract/Free Full Text]
|
| 44.
|
Khan, W. A.,
Blobe, G. C.,
and Hannun, Y. A.
(1995)
Cell. Signal.
7,
171-184[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Graber, R.,
Sumida, C.,
and Nunez, E. A.
(1994)
J. Lipid Mediat. Cell Signal.
9,
91-116[Medline]
[Order article via Infotrieve]
|
| 46.
|
Chuang, T. H.,
Bohl, B. P.,
and Bokoch, G. M.
(1993)
J. Biol. Chem.
268,
26206-26211[Abstract/Free Full Text]
|
| 47.
|
Shin, E. A.,
Kim, K. H.,
Han, S. I., Ha, K. S.,
Kim, J. H.,
Kang, K. I.,
Kim, H. D.,
and Kang, H. S.
(1999)
FEBS Lett.
452,
355-359[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Eom, Y. W.,
Cho, S. H.,
Hwang, J. S.,
Yoon, S. B., Na, D. S.,
Kang, I. J.,
Kang, S. S.,
Song, W. K.,
and Kim, J. H.
(2001)
Biochem. Biophys. Res. Commun.
284,
126-132[CrossRef][Medline]
[Order article via Infotrieve]
|
| 49.
|
Wolf, B. A.,
Turk, J.,
Sherman, W. R.,
and McDaniel, M. L.
(1986)
J. Biol. Chem.
261,
3501-3511[Abstract/Free Full Text]
|
| 50.
|
Blobe, G. C.,
Khan, W. A.,
and Hannun, Y. A.
(1995)
Prostaglandins Leukotrienes Essent. Fatty Acids
52,
129-135[CrossRef][Medline]
[Order article via Infotrieve]
|
| 51.
|
Balsinde, J.,
Balboa, M. A.,
Yedgar, S.,
and Dennis, E. A.
(2000)
J. Biol. Chem.
275,
4783-4786[Abstract/Free Full Text]
|
| 52.
|
Osterhout, J. L.,
and Shuttleworth, T. J.
(2000)
J. Biol. Chem.
275,
8248-8254[Abstract/Free Full Text]
|
| 53.
|
Naccache, P. H.,
McColl, S. R.,
Caon, A. C.,
and Borgeat, P.
(1989)
Br. J. Pharmacol.
97,
461-468[Medline]
[Order article via Infotrieve]
|
| 54.
|
Schatz-Munding, M.,
Hatzelmann, A.,
and Ullrich, V.
(1991)
Eur. J. Biochem.
197,
487-493[Medline]
[Order article via Infotrieve]
|
| 55.
|
Qiu, Z. H.,
Gijon, M. A.,
deCarvalho, M. S.,
Spencer, D. M.,
and Leslie, C. C.
(1998)
J. Biol. Chem.
273,
8203-8211[Abstract/Free Full Text]
|
| 56.
|
Gijon, M. A.,
Spencer, D. M.,
Kaiser, A. L.,
and Leslie, C. C.
(1999)
J. Cell Biol.
145,
1219-1232[Abstract/Free Full Text] |